At the 2023 ASRS meeting in Seattle, Washington, Aaron Lee, MD, spoke with our team about his research and how changes are making new training possible. He shared how research and new techniques are expanding the options for deep learning in ophthalmology.
The company noted at the American Society of Retina Specialists meeting in Seattle the phase 2 Dose Expansion (N=50) initial interim efficacy and safety data presentation expected at medical conference in H1 2024.
Jennifer I. Lim, MD, FARVO, FASRS shares insights from her presentation on "Detection of early diabetic retinopathy using OCT-A blood flow analysis."
Our team caught up with Baruch Kupperman, MD, PHD who is presenting, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease" to learn more about this topic.
With the potential to impact millions of patients, a study finds that biomimetic materials pulsed with low-energy blue light can reshape damaged corneas, including thickening the tissue.
The College of Health Care Professions will offer a blended 36-week certificate program to meet the growing demand for ophthalmology assistants across the Dallas-Forth Worth region.
The intraocular injection of AXT107 microparticulate suspension will be explored in the DISCOVER study.
The company announced it has scheduled an End-of-Phase 2 meeting with the FDA in Q4 2023 to discuss the specifics of the APX3330 development program.
OPT-302 is the company’s novel recombinant “trap” fusion protein targeting inhibition of vascular endothelial growth factors C and D, two ligand mediators of angiogenesis and vascular leakage involved in retinal vascular diseases.
HLX04-O has the potential to be one of the first bevacizumab approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.
According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% (XDEMVY) is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.
According to the companies, this partnership will leverage RetinAI's innovative digital health technologies and RCA's network of clinics to analyze real-world health clinical and imaging data.
According to the company, Megan Baldwin, PhD, CEO of Opthea Ltd, will provide an overview of the company’s Phase 3 clinical program advancing OPT-302 for the treatment of wet AMD.
According to the University of Barcelona, the agreement between DBGen Ocular Genomics and Novartis will allow the accurate diagnostics of the genetic bases of these two pathologies to be conducted by mass sequencing of gene panels designed by the UB spin-off.
According to The Fred Hollows Foundation, an estimated $12 trillion could be added to global output by 2025 if the gender gap was closed in both the workforce and leadership.
The surgery provides one of the largest investment returns of any disease intervention.
Cedars-Sinai research is the first to uncover disease-related changes to the cornea and to propose potential therapeutic approaches to correct diabetic wound healing.
Francesca Marassi, PhD, and her collaborators have received a $13 million National Institutes of Health grant to study misplaced calcified deposits that are a misunderstood factor in common diseases of aging, including age-related macular degeneration.
Faricimab is currently approved in more than 70 countries to treat nAMD and DME, with more than 1 million doses distributed globally, and Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists annual meeting in Seattle.
The American Society of Retina Specialists is holding its 2023 annual meeting July 28 through August 1 at the Seattle Convention Center in downtown Seattle.
Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of omidenepag isopropyl ophthalmic solution in the United States.
According to the ASRS Research and Safety in Therapeutics Committee, ophthalmologists noted instances of intraocular inflammation (IOI) after the initial injection of pegcetacoplan.
SriniVas R. Sadda, MD, discusses being president-elect of ARVO, as well as AI research being conducted at Doheny Eye Institute.
According to the company, the transaction includes U.S. and Canadian commercial rights to six therapeutics, including two non-prescription brands.
According to the company, initial interim Phase 2 efficacy data is expected to be presented in H1 2024. It also is expected to provide an update regarding Phase 3 pivotal trial plans in Q1 2024 after discussion with the FDA later this year.
A trial funded by the National Institutes of Health underscores need for more research to head off high myopia.
According to a study, the experimental eye drop treatment was twice as effective as the standard injection therapy at reducing swelling and improving blood flow within the retina of mice with RVO.
According to researchers at Duke University Medical Center, the tool demonstrates the potential for a non-invasive and inexpensive way to diagnose a common precursor of Alzheimer’s disease.
The skills highlighted during the session are some of the most important tools in an ophthalmologist’s toolbelt and learning and practicing them early, even as a medical student, is crucial.
.png "Optometry Times"){kind=logo}
